A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Moderate-to-severe tricuspid regurgitation (TR) has a high prevalence in the general population, 1 and it progressively increases in older individuals, in whom it is close to 4%.

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

The key to treating congestive heart failure is addressing the underlying causes, and treatment is highly tailored to each ...

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...